Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Next Previous
Trial Profile

Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezatomidine (Primary)
  • Indications Fibromyalgia; Pain
  • Focus Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
  • 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 09 May 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified February 2009).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top